Citi raised the firm’s price target on Prime Medicine (PRME) to $5 from $4 and keeps a Neutral rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- PRME Earnings this Week: How Will it Perform?
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks
- Cathie Wood’s ARK Investment buys 231K shares of Prime Medicine today
- PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
- Cathie Wood’s ARK Investment buys 157.4K shares of Prime Medicine today